The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

US FDA extends the review period for GSK’s Blenrep combinations to treat relapsed/refractory multiple myeloma: London, UK Friday, July 25, 2025, 11:00 Hrs [IST] GSK plc announce ...

The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with ...

Among reasons for the rejection, the agency cited a lack of US patient representation in the STARGLO trial assessing ...

London: GSK plc has announced the extension of the US Food and Drug Administration (FDA) review period for the Biologics ...

The FDA’s approval of linvoseltamab for adults with heavily pretreated relapsed/refractory multiple myeloma marks a significant advance, with Sundar Jagannath, MBBS, emphasizing its high response ...

GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with ...

In this video, Sham Mailankody, MBBS, discusses results from the long-term follow-up of CARTITUDE-1 patients receiving ciltacabtagene autoleucel, or cilta-cel, for the treatment of relapsed or ...

Background: Improving the safety of epcoritamab by reducing the incidence and severity of CRS and ICANS may enhance its accessibility and reduce healthcare resource utilization. In the pivotal EPCORE ...